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Purpose: To describe the 1-year success of a trabecular stent implant in a pseudophakic 
glaucoma patient. The stent is implanted through a small corneal incision under gonioscopic 
control. Intraocular pressure control was reported in cultured human anterior segment.
Design: Observational case report.
Methods: We report the case of a patient who was implanted and followed-up for 1 year at the 
Dipartimento di Fisiopatologia Clinica. The main outcome measures were intraocular pressure 
and visual ﬁ  eld.
Results: The patient’s intraocular pressure was controlled with topical beta-blockers for 
6 months and without therapy for 6 months. Two diurnal curves demonstrated achievement of 
target pressure during the day. The 1-year visual ﬁ  eld was unchanged.
Conclusions: We are not aware of previous reports of trabecular stent implantation in pseu-
dophakic patients. The trabecular stent had minimal peri-operative morbidity. Identiﬁ  cation of 
the implantation site is challenging and reduction of efﬁ  cacy over time may occur.
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Introduction
Glaucoma in pseudophakic eyes is not uncommon; both trabeculectomy and deep scle-
rectomy failure have been reported in the literature with higher rates in pseudophakic 
eyes than in unoperated eyes (Fontana et al 2006). The iStent (Glaukos Corp, Laguna 
Hills, CA, USA) is a heparin-coated titanium device that can be inserted ab interno 
in the trabecular meshwork under gonioscopic control, driving the aqueous into the 
Schlemm’s canal; it can lower intraocular pressure (IOP) in cultured human anterior 
segments (Bahler et al 2004). The device inserted ab interno has shown to be clinically 
effective when used concomitantly with phacoemulsiﬁ  cation (Feijoo et al 2006). We 
report a case of a pseudophakic glaucoma patient who achieved target pressure after 
the implant of the trabecular bypass stent.
Case report
A 68-year-old patient with primary open-angle glaucoma (POAG) underwent 
uncomplicated phacoemulsiﬁ  cation (OD) and presented with elevated IOP in the operated 
eye 1 month postoperatively. Her prior medical history is as follows: renal colic with a 
diagnosis of nephrolitiasis, which was medically controlled and a previously reported 
intolerance to prostaglandin analogues. Additionally, the patient reported disinterest in 
further invasive surgery. See Table 1 for complete baseline information.
After the initial phaco surgery, her postop regimen consisted of steroids for 1 week, 
tapered over 2 weeks. At Day 10 follow-up, IOP in the operated eye was 19 mm Hg 
(14 mm Hg in the contralateral eye). Also at Day 10, the right visual ﬁ  eld had a fascicular 
scotoma impending on the macular region, and a superior notch of the optic nerve head. 
By 1 month postoperation, her IOP had increased to 30 mm Hg OD (and to 15 mm Hg Clinical Ophthalmology 2008:2(4) 932
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in the nonoperated eye). At that time, she was on dorzolamide 
TID in both eyes, with the addition of brimonidine in the 
right eye only twice daily. At this follow-up, there were no 
signs of inﬂ  ammation and steroids were not felt responsible 
for the IOP rise because they had already been stopped 
and IOP was normal while she was on steroid treatment 
(ie, previous control at 10 days). She was followed every 
2 weeks for an additional 2 months (3 months after initial 
phaco). Target pressure (IOP  18 mm Hg) was achieved 
(IOP ranged from 12 to 17 mm Hg) with added medical 
therapy (acetazolamide ½ 250 mg tablet TID). Following a 
signiﬁ  cant eyelid and conjunctival allergic reaction, she was 
switched to preservative-free carteolol 2%, brimonidine, and 
topical steroids. Inﬂ  ammation returned after steroid use was 
discontinued.
To attempt better management of her glaucoma, her 
therapy was changed to preservative-free carteolol 2% BID 
and acetazolamide 250 mg TID. She was able to achieve 
target IOP of 18 mm Hg on maximum therapy, but did 
not want additional invasive surgery after an unsuccessful 
argon laser trabeculectomy was performed to avoid the use 
of systemic drugs.
Following a renal cholic, the patient agreed to the 
iStent implantation, as she did not view the procedure as 
invasive.
The device itself is a small L-shaped hollow tube 
designed to be implanted into Schlemm’s canal by having 
the surgeon make a slit through the trabecular meshwork. 
The iStent is designed for nasal placement and is guided 
into Schlemm’s canal using ab interno gonioscopy. In this 
patient, a nasal clear corneal 2 mm incision was made. The 
anterior chamber was then ﬁ  lled with a viscoelastic agent to 
reform the anterior chamber and provide more clearance in 
the angle. The surgeon (AMF) ensured the orientation of the 
stent on the applicator, placed the gonioscope on the cornea, 
and positioned the microscope to enable visualization of 
the trabecular meshwork. The anterior chamber was then 
traversed with the applicator. The leading edge of the iStent 
was eased through the meshwork and into the canal, with the 
tip directed inferiorly.
On the ﬁ  rst postoperative day, her vision OD was main-
tained (25/20), few red cells were present in the anterior 
chamber, IOP was well controlled (12 mm Hg), and the stent 
was correctly placed in the angle (Figure 1). When pressure 
was applied to the goniolens, small blood reﬂ  ux could be seen 
sideways from the stent and some blood was reabsorbed by 
the stent snorkel (video). Pressure was monitored monthly 
for 6 months and was always lower than 17 mm Hg (range: 
12–16 mm Hg) on carteolol; IOP remained 17 mm Hg 
during the day.
At 6 months, the stent remained in place and unobstructed 
(Figure 2, left); the UBM (Figure 2, right) demonstrated that the 
snorkel of the stent was adequately placed in the angle. Topical 
therapy was then discontinued OD and the patient followed 
for an additional 6 months (1 year after stent implantation). 
The IOP in the right eye remained 18 mm Hg (mean 14.9 ± 
1.7; range: 13–17 mm Hg). A diurnal curve without therapy 
demonstrated IOP 17 mm Hg (range: 12–16 mm Hg). The 
1-year visual ﬁ  eld and CCT were unchanged.
Discussion
We are reporting on our own successful experience using a 
trabecular stent in a pseudophakic eye using an ab interno 
approach. Our experience mimics that of other surgeons using 
the stent in patients who were not pseudophakic (Spiegel 
et al 2007), suggesting the stent’s efﬁ  cacy in controlling 
glaucoma may not be limited to just virgin eyes. There is 
currently under way a larger clinical study of 47 patients 
with cataract and open-angle glaucoma to directly compare 
results in IOP lowering between those implanted with stents 
to those undergoing cataract surgery only and using medical 
therapy to manage their glaucoma.
Of note, in combined surgery, the ability for the surgeon 
to use the clear corneal incision created during cataract 
surgery can be advantageous, as there is no need for cau-
tery and the conjunctiva and sclera are not disturbed. In 
this technique, a traditional glaucoma surgical procedures 
such as trabeculectomy would not be negatively affected 
(Samuelson 2007).
In this case study, the patient presented with a high IOP 
1 month following uneventful cataract surgery and with-
out any sign of inﬂ  ammation. It is unlikely that steroids 
might have caused this IOP rise because they had already 
been tapered. The patient had a trabecular bypass stent 
Table 1 Clinical characteristics at baseline
Medical history  Asthma
 NIDDM
Previous surgery  Pace maker implantation (2000)
  LE cataract surgery (2003)
Glaucoma therapy  OU: dorzolamide tid
  RE: Brimonidine bid
  Acetazolamide 250 mg ½ tablet tid
IOP  RE: 19 mm Hg
  LE: 10 mm Hg
Central corneal thickness  RE: 535
 LE:  543Clinical Ophthalmology 2008:2(4) 933
After implant of trabecular bypass stent in pseudophakic glaucoma
Figure 1 The stent is seen correctly placed at the trabecular meshwork level.
Figure 2 Left: The gonioscopic view of the stent. Right: The UBM shows the hyperechogenic structure of the stent (circle), placed below the corneal wedge (arrow).Clinical Ophthalmology 2008:2(4) 934
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inserted through a 2 mm temporal corneal incision. The 
stent implantation was successful in maintaining IOP less 
than 17 mm Hg. A key to a successful surgery is the need 
of correct identiﬁ  cation of Schlemm’s canal and therefore 
proper placement of the stent. Although in enucleated eyes, 
the mean postoperative IOP averaged 12.4 mm Hg. In our 
patient, the mean IOP was slightly higher (14.9 mm Hg), 
possibly due to limited circumferential ﬂ  ow in Schlemm’s 
canal. Additional stent placement might result in further 
IOP lowering as suggested by in vitro models (Bahler et al 
2004). Longer-term IOP reduction has to be assessed with 
regard to continuous lumen clearance or possible future 
trabecular ﬁ  brosis.
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